Posts for Ticker ‘ONTY’

Long Line of Biotech Secondary Stock Offerings (MNKD, IDIX, ISPH, ARIA, ONTY, NBY, SOMX, ARNA, OXGN)

Money Stack ImageIt seems that there is another endless line of biotech and emerging pharmaceutical companies which have raised cash or have filed to raise cash.  MannKind Corporation (NASDAQ: MNKD), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), and Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) have all priced secondary offerings of common stock for close to $175 million total among all three offerings this morning alone.  Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) had its pricing yesterday of a secondary offering and Oncothyreon Inc. (Nasdaq: ONTY) announced terms for a direct offering of securities.   NovaBay Pharmaceuticals, Inc. (NYSE: NBY) filed this week for a capital raise.

Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), and OXiGENE, Inc. (NASDAQ: OXGN) have all filed this week with the SEC for the resale of securities by secondary offering and private placement buyers in recent weeks.

You can read the full story with details on each offering over at BioHealthInvestor.com.

And imagine this… it is only Wednesday.

-The 24/7 Wall St. Team

Posted on: August 5, 2009 – 1:28 pm in Biotech, Secondary Offering, , , , , , , , ,

Top Day Trader Alerts (SVNT, HURN, RPRX, EBAY, HUM, ONTY)

The following are among the top day trader and active trader alert stocks with major price and volume action.  We have links to more detailed analysis and price action at VSInvestor.com:

Savient Pharmaceuticals (NASDAQ: SVNT) is among the worst performers on disappointing FDA action on its gout treatment.

Huron Consulting Group Inc. (NASDAQ: HURN) is the worst performer on earnings restatements and management being replaced.

Repros Therapeutics (NASDAQ: RPRX) is down sharply by over 50% after stopping trials on patient safety.

eBay Inc. (NASDAQ: EBAY) is up over 4% after getting the barron’s cover story.

Humana Inc. (NYSE: HUM) is up over 4% on higher earnings growth.

Oncothyreon Inc. (NASDAQ: ONTY) is up big on lung cancer study data.

The 24/7 Wall St. Team

Posted on: August 3, 2009 – 8:38 am in Pre-Market Activity, Trading Alert, , , , , ,

Oncothyreon Cleared To Raise Cash (ONTY)

Oncothyreon Inc. (NASDAQ: ONTY), a therapeutic cancer treatment biotech firm, announced today that the SEC has made their filing for periodic offering of up to $50,000,000 in securities effective. The offering was filed March 20 and will allow them to offer from time to time any combination of common stock, debt securities, warrants, preferred stock, and depository shares. The proceeds will be used to fund clinical trials, finance capital expenditures, or for general working capital uses. Also on March 20, they were issued a patent for PX-867, a small molecule compound in the pre-clinical development stages for cancer and cardiovascular treatments.

Shares have hardly reacted to the news, and are flat today at $2.78 on somewhat light trading for a very thin volume stock. The 52-week range is $1.47 to $8.82.

You can join our open email distribution list to hear about special financings, secondary offerings, IPO’s, M&A, and more previews for other special situations in various stages.

Rachel Lopez
April 9, 2008

Posted on: April 9, 2008 – 11:50 am in Biotech, Secondary Offering,